SCRIBE THERAPEUTICS
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to ground... breaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
SCRIBE THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.scribetx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
120 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Google Apps For Business
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellington Management
Wellington Management investment in Series B - Scribe Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - Scribe Therapeutics
Avoro Ventures
Avoro Ventures investment in Series B - Scribe Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series B - Scribe Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Scribe Therapeutics
OrbiMed
OrbiMed investment in Series B - Scribe Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Scribe Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Series B - Scribe Therapeutics
Menlo Ventures
Menlo Ventures investment in Series B - Scribe Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series A - Scribe Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-09 | Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller |
Official Site Inspections
http://www.scribetx.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Scribe Therapeutics"
Scribe → About - scribetx.com
Scribe is rewriting medicine with molecular engineering. Jennifer Doudna is the Li Ka Shing Chancellor's Chair and a Professor in the Departments of Chemistry and of Molecular and Cell …See details»
Scribe Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR …See details»
Scribe Therapeutics - LinkedIn
Benjamin Oakes, Ph.D., Scribe Therapeutics cofounder and CEO, spoke about what the next generation of therapies looks like at the 2024 Forbes Healthcare Summit in New York City. …See details»
Scribe → Platform
Discovery. Naturally occurring CRISPR systems have revolutionized genetic medicine since 2012, when their potential for gene editing was unlocked in the lab of our co-founder, Nobel Laureate …See details»
Scribe Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse
To learn more, visit www.scribetx.com . 10 May 2024 ... The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is …See details»
Scribe Therapeutics Company Profile 2024: Valuation, …
Scribe Therapeutics General Information Description. Developer of molecular engineering technologies designed to treat genetic diseases. The company's platform offers biological preparations based on engineered cells for medical …See details»
Scribe Therapeutics - Overview, News & Similar companies
Mar 14, 2024 www.scribetx.com. Revenue $6 Million. Industry Manufacturing General Manufacturing . Most Recent Scoops. Apr 23 2024. Open Position . Mar 15 2024. Open …See details»
Scribe Therapeutics - Golden
Scribe develops gene-editing therapies based on CRISPR-CasX, an RNA-guided genome-editing platform. The company was founded in 2018 by Jennifer Doudna, Benjamin Oakes, David F. …See details»
About SCRIBE THERAPEUTICS | DxMultiomics
Scribetx.com. Mark. Scribe Therapeutics is revolutionizing the development of optimized genetic medicines that have the potential to durably treat disease at scale. Scribe's CRISPR by …See details»
Scribe Therapeutics Company Profile -Sales, Contacts, Competitors ...
Www.scribetx.com: Scribe Therapeutics Inc. is the only company located at 1150 MARINA VILLAGE PKWY, Alameda, CA 94501 ... Research, and Management Services sector. This …See details»
Scribe Therapeutics Appoints David Parrot as Chief Financial …
Mar 9, 2022 “We are delighted to have David and George join Scribe and provide key leadership in our finance team at a time of significant growth for our organization,” said Benjamin Oakes, …See details»
Scribe Therapeutics - workinbiotech.com
Scribe Therapeutics is engineering new therapeutics using CRISPR. The underlying causes of many genetic diseases can be treated through gene editing. Scribe is focusing on in vivo …See details»
Scribe Therapeutics Presents Data Demonstrating Highly Potent …
ALAMEDA, Calif., May 10, 2024--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor …See details»
Scribe Therapeutics Raises $100M Series B Financing to Further …
Mar 31, 2021 To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com. Contacts Thermal for Scribe Therapeutics Kaustuva Das [email protected] …See details»
Scribe → Pipeline - scribetx.com
Low-density lipoprotein cholesterol (LDL-C) is a key driver of dyslipidemia and cardiovascular risk. Elevated LDL-C levels in the bloodstream can promote the formation of plaques in arterial …See details»
Dr. Benjamin Oakes, Ph.D. - CEO, Scribe Therapeutics - YouTube
Dr. Benjamin L. Oakes, Ph.D., is Co-Founder, President, and Chief Executive Officer at Scribe Therapeutics ( https://www.scribetx.com/ ), a molecular enginee...See details»
Benjamin Oakes Email & Phone Number - ZoomInfo
Benjamin Oakes contact details: Email address: b***@scribetx.com Phone number: (***) ***-**** Who is Benjamin Oakes? Benjamin L. Oakes, PhD, is Co-founder, President, and Chief …See details»
Scribe → Scribe Therapeutics Expands Collaboration With Biogen …
May 2, 2022 The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the …See details»
Scribe → Privacy Policy - scribetx.com
Scribe Therapeutics (“us”, “we”, or “our”) operates the scribetx.com website and the new horizon mobile application (the “Service”). This page informs you of our policies regarding the …See details»